A recent Spanish study concludes that CT-P13, a biosimilar of reference infliximab that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).
A recent Spanish study published in Digestive Diseases and Sciences concludes that CT-P13 (Remsima, Inflectra), a biosimilar of reference infliximab (Remicade) that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).
Federico Argüelles-Arias, MD, PhD, and colleagues conducted a preliminary observational trial in patients in Spain with inflammatory bowel disease who were either naïve to anti-tumor necrosis factor (anti-TNF) treatment or who were switched from reference infliximab to CT-P13. Efficacy and safety were assessed at months 3 and 6 of therapy in both the treatment-naïve patients and in switched patients who were in remission at the time of the switch. All patients received intravenous corticosteroids and antihistamines as premedication prior to the infusion treatment.
A total of 80 CD patients and 40 UC patients were included in the study. Among the CD patients, 13 (16.25%) were naïve to anti-TNF and 67 (83.75%) were switched from reference infliximab to CT-P13. At the time of the switch, 56 of the 67 patients (83.5%) were in remission. Median duration of ongoing reference infliximab treatment at the start of the study was 297 weeks.
Over the course of the study, 6 participants were excluded (1 did not attend follow-ups, 3 had adverse events, 1 had no response to treatment, and 1 was referred to surgery).
Of the 40 UC patients, 9 (22.5%) were naïve to anti-TNF (6 of these 9 patients had treatment with steroids), and 31 (77.5%) were switched from reference infliximab to CT-P13. A total of 25 out of 31 of the UC switched patients were in remission at the time of the switch.
The researchers found that 87.5% of switched patients with CD who were previously in remission remained so, and 66.7% and 50% of treatment-naïve patients with CD reached remission at months 3 and 6, respectively.
In switched patients with UC, 92% and 91.3% of patients in remission at the time of the switch maintained remission at 3 and 6 months, respectively. In treatment-naïve patients with UC, the remission rates were 44.4% and 66.7% at months 3 and 6, respectively.
The researchers report that there were serious adverse events (AEs) in 9 patients (7.5%), 6 of whom discontinued treatment due to AEs, which included the following:
The researchers concluded that CT-P13 was efficacious and well tolerated in patients with CD or UC. “Response was maintained in 84% of switched CD and in 91.3% of switched UC patients, and clinical remission was reached in 50% of naïve CD and 70% of naïve UC patients,” they said, demonstrating the effectiveness and safety of CT-P13 at 3 and 6 months. However, continuing assessment of response in these patients over a longer period is necessary.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).